Renal and Biliary Lithotripsy Using a Medstone 1050 Lithotripter
With FDA approval in 1988 of biliary lithotripsy trials in the United States, the manufacturers of lithotripters have sought to produce a multipurpose lithotripter that will perform successfully both renal and biliary lithotripsy. From August 1988 to February 1989 (7 months) the Medstone 1050 lithotripter was used to perform renal lithotripsy on 388 patients and biliary lithotripsy on 40 patients. There was a 7% retreatment rate in the 388 patients having renal lithotripsy and a 2% secondary endoscopic or percutaneous procedures post-lithotripsy. At two month follow-up 73% were stone free, and 14% had fragments smaller than 4 mm.
In 40 patients having biliary lithotripsy there was a significant stone size reduction in 22 patients (81%) with single stones, and in 18 patients (71%) with multiple stones. The retreatment rate was 20%, and no patient required a secondary endoscopic or surgical procedure. All patients will take ursodeoxycholic (UDC) acid for six months post-lithotripsy. The Medstone 1050 lithotripter is a multipurpose lithotripter successful in treating both urinary and biliary stones.
KeywordsShock Wave Shock Wave Lithotripsy Renal Stone Extracorporeal Shock Wave Lithotripsy American Urologic Association
Unable to display preview. Download preview PDF.
- 3.American Urological Association Ad Hoc Committee to Study the Safety and Clinical Efficacy of Current Technology of Percutaneous Lithotripsy and Noninvasive Lithotripsy Report. Baltimore: American Urological Association, Inc., 1985.Google Scholar